Worldwide, the number of kidney failure patients receiving the life saving treatment, dialysis, is estimated at more than 2 million, with the incidence growing by approximately 8% annually. Only about 10% of dialysis patients are treated with a form of dialysis known as Peritoneal Dialysis (PD) eventhough PD is preferred by both patients and payers. PD is preferred by patients because they enjoy a better physical and psychological quality of life and have lower mortality rates compared to Hemodialysis (HD) patients (the dominant in-clinic dialysis treatment). PD is preferred by payers because it is home-based therapy and on average it costs 35% or 43 500 USD less per year to provide health care to a PD patient compared to HD.
Although many patients start dialysis on PD they need transition to HD for a number of different reasons. Triomed has developed a modular dialysis system that addresses the key reasons patients leave PD, and adapts to treat the patient in the different stages of their disease progression.
Triomed’s patent protected Carry Life systems are based on the innovative concept – Steady Concentration PD (SCPD). By continually recirculating and regenerating the patient’s dialysate fluid, Carry Life is able to maintain a constant gradient over the patient’s peritoneal membrane, which traditional forms of PD cannot do. This constant gradient leads to a significant increase in the removal water and salt from the patient (ultrafiltration) and in combination with Triomed’s patent protected cartridge Purecart, an increase in the amount of toxins that can removed from the patient.
The Carry Life system therefore addresses the key reasons patients leave PD for HD.
Triomed AB is a MedTech company based at the Ideon Science Park in Lund, Sweden.
Member of the Board of Directors since 2012. Ugo Grondelli has a Masters of Science in Business and Economics with an MBA from UCLA (University of California). Grondelli owns, Spindial Europé S. A., a company within the dialysis and intensive care market. Grondelli is a member of the board of Alteco AB in Lund, a medical technology company. Previous experience includes Executive Vice President within the Gambro group, Chairman of the Board of Hospal AG, Switzerland, Vice President of Jostra AG, Germany, and board member of Q-Med AB.
Member of the Board of Directors since 2012. Co-founder of Triomed. Since the beginning of the 1990s, Anders Helmner has successfully driven the development, production and distribution of components for medium-haul commercial aircraft. He has also built up the global distribution of components for long-haul commercial aircraft.
Member of the Board of Directors since 2012. Lars Persson represents Almi Invest. He has long experience from leading positions in MedTech and Venture Capital. Previously, Persson worked at Industrifonden and Atos Medical AB and he sits on the Board of a number of medical technology companies.
Chairman of the Board since 2016.
Wahlström is the Executive Chairman of KMG Capital Partners, LLC and Chairman of Surefire Medical, Inc and a Board member of Coherus Biosciences Inc, Alteco Medical AB,PCI HealthDey, LLC and Empirican Group, Inc. Wahlström has more than 30 years of international experience in health care from such positions as CFO and Executive Vice President of the Gambro Group and as CEO of Gambro Healthcare Inc. He has also served as Co-CEO of Fresenius Medical Care North America, CEO of Fresenius Medical Services, and was a member of the Management Board for Fresenius Medical Care AG & Co. KGaA.
Ulf Öjerklint is a lawyer and senior partner at Gärde Wesslau law firm and has been practising business law since 1984. Öjerklint has conducted a large number of transactions comprising extensive commercial agreements combined with establishment of various legal structures. In addition, he has assisted numerous clients in structured procedures regarding sales and acquisitions of companies as well as financial assignments in order to generate funds on the venture capital market. Öjerklint is active in a number of corporate boards.
Member of the Board of Directors since 2016. Co-founder of Triomed. Anders Wallenås is a Master of Science in Engineering, Mechanical Engineering and has more than 30 years’ experience of running industrial development projects. He has been operative in various industries with the development of products all the way from the early stages to a commercial product. Anders Wallenås is a board member of Avena Energi AB in Lund.
Member of the Board of Directors since 2016. Dr Bosch is a Nephrologist with extensive experience in Clinical Medicine, Neprology and research in Artificial Organs.He has written over 100 papers in the field. Has has occupied Academic positions in USA Medical Schools and reached the Title of Professor withTenure at George Washington University in Washington DC.
Patrick Greatrex, BA, LLB, MBA
Patrick Greatrex has been the CEO of Triomed since 2016. Prior to joining Triomed Patrick had a number of CEO and senior management roles in life science companies including CEO of Vivoline Medical AB and Vice President of Business Development at Gambro AB. Patrick has been awarded Bachelor Degrees in Law and Arts from the University of Queensland and an MBA from Lund University.
Nina Meinander, PhD
R&D Chemistry Manager
Nina Meinander joined Triomed AB in 2012 as Manager of the Chemistry R&D Team, and leads the development of adsorbent devices for purification of dialysis fluid. Nina Meinander has 13 years’ experience from pharmaceutical R&D, and has an MSc in Chemical Engineering and a PhD in Applied Microbiology/Biotechnology.
Hans Bengtsson, MSc
R&D Product Development Manager
Hans Bengtsson joined Triomed AB in 2012 as Manager of the Mechanics and Electronics R&D team, and leads the development of Triomed products. Hans Bengtsson has an MSc in Mechanical Engineering and more than 20 years’ experience of leading R&D projects.
Triomed AB is ISO 13485:2016 certified for the design and development, production, distribution and service of devices for extra-corporal circulation, infusion and haemopheresis and injection, transfusion and dialysis.
Carry Life Renal and Carry Life UF are under development and are not for sale - Copyright Triomed 2018